These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha. Kast RE; Altschuler EL J Rheumatol; 2008 Aug; 35(8):1679; author reply 1679-80. PubMed ID: 18671327 [No Abstract] [Full Text] [Related]
7. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Gerloni V; Pontikaki I; Gattinara M; Fantini F Ann Rheum Dis; 2008 Aug; 67(8):1145-52. PubMed ID: 17981916 [TBL] [Abstract][Full Text] [Related]
8. Reactivation of latent granulomatous infections by infliximab. Wallis RS; Broder M; Wong J; Lee A; Hoq L Clin Infect Dis; 2005 Aug; 41 Suppl 3():S194-8. PubMed ID: 15983899 [TBL] [Abstract][Full Text] [Related]
9. Summaries for patients. Tumor necrosis factor antagonists and heart failure. Ann Intern Med; 2003 May; 138(10):I48. PubMed ID: 12755581 [No Abstract] [Full Text] [Related]
13. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811 [TBL] [Abstract][Full Text] [Related]
14. Arthralgia as an adverse event to infliximab: a reactive arthritis or triggering of psoriatic arthritis? Successful management by switching to etanercept. Moustou AE; Stratigos AJ; Vergou T; Gregoriou S; Georgala S; Danopoulou I J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):968-9. PubMed ID: 19207660 [No Abstract] [Full Text] [Related]
15. Tumor necrosis factor and granuloma biology: explaining the differential infection risk of etanercept and infliximab. Wallis RS; Ehlers S Semin Arthritis Rheum; 2005 Apr; 34(5 Suppl1):34-8. PubMed ID: 15852254 [TBL] [Abstract][Full Text] [Related]
16. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Wallis RS Arthritis Rheum; 2008 Apr; 58(4):947-52. PubMed ID: 18383389 [TBL] [Abstract][Full Text] [Related]
17. [Indications and adverse events with the use of anti-TNFalpha agents in pediatric rheumatology: experience of a single center]. de Oliveira SK; de Almeida RG; Fonseca AR; Rodrigues MC; Sztajnbok F; Diniz C Acta Reumatol Port; 2007; 32(2):139-50. PubMed ID: 17572652 [TBL] [Abstract][Full Text] [Related]
18. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Galor A; Perez VL; Hammel JP; Lowder CY Ophthalmology; 2006 Dec; 113(12):2317-23. PubMed ID: 16996615 [TBL] [Abstract][Full Text] [Related]
20. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Carroll MB; Bond MI Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]